H.C. Wainwright analyst Sean Lee lowered the firm’s price target on CytoSorbents (CTSO) to 75c from $1 and keeps a Neutral rating on the shares. The firm reduced estimates to reflect to the “continued drag” on the company’s Germany revenues.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTSO:
- CytoSorbents Reports Strong Q3 2025 Growth and Strategic Advances
- CytoSorbents reports Q3 adjusted EPS (4c), consensus (5c)
- CytoSorbents implemented workforce and cost reduction program
- CTSO Upcoming Earnings Report: What to Expect?
- Cytosorbents Corp’s Latest Study Update: A Game Changer in Critical Care?